Compound evidence index
27 profiles covering approved medicines, clinical-trial candidates, preclinical substances and related products. Inclusion is not endorsement. Each profile identifies the evidence type, United States status, formulation limits and primary sources.
Adamax
Adamax is described as a modified Semax analogue and is claimed to support concentration, memory and mental stamina. Those effects have not been tested in Adamax-specific human research, and its chemical identity is not consistently established. [1,2]
Status: Not FDA-approved. [1–2] Evidence: No compound-specific human clinical evidence located
AOD-9604
AOD-9604 was designed to promote fat breakdown without the broader effects of growth hormone. The largest 24-week human trial reviewed by FDA found less than 1 kg of average weight loss and no significant difference from placebo. [1]
Status: Not FDA-approved. [1] Evidence: Human development did not establish weight-loss efficacy
BPC-157
BPC-157 is claimed to reduce pain and speed recovery from tendon, ligament, muscle and gut problems. A small knee series recorded self-reported pain improvement, and online recovery claims are widespread, but neither establishes tissue healing. [1–5]
Status: No FDA-approved BPC-157 product Evidence: Preclinical studies and small human reports
Cerebrolysin
Cerebrolysin is a pig-brain-derived mixture intended to help damaged brain cells survive and maintain connections. After a stroke, the hoped-for result is better movement, speech, memory or independence, but a 2023 Cochrane review did not establish that benefit. [1,2]
Status: Not FDA-approved. [1–2] Evidence: Clinical trials; uncertain benefit and a possible serious-adverse-event signal
CJC-1295 and modified GRF
CJC-1295 stimulates growth-hormone release and can raise IGF-1. It is claimed to improve sleep, muscle, fat loss and recovery, but human studies measured hormone levels rather than those practical outcomes. DAC and no-DAC products are different molecules. [1–4]
Status: No FDA-approved CJC-1295 product Evidence: Early human hormone studies; formulation matters
Dihexa
Dihexa is claimed to improve learning and memory by helping brain cells form stronger connections. The central 2014 paper behind that theory and its extreme potency claim was retracted in April 2025. [1–3]
Status: Not FDA-approved. [1–3] Evidence: Preclinical evidence undermined by a foundational retraction
DSIP
DSIP is named for a proposed link to deep sleep and is claimed to support more restful sleep without a conventional sedative. Studies have not shown reliable improvements in insomnia, nighttime waking or next-day function. [1,2]
Status: Not FDA-approved. [1–2] Evidence: Old, small and inconsistent human literature
Elamipretide
Elamipretide binds a mitochondrial membrane component involved in energy production. Forzinity is approved to improve muscle strength in eligible people with Barth syndrome, not to treat ordinary fatigue, enhance sport or slow aging. [1–5]
Status: FDA accelerated approval for Barth syndrome in patients weighing at least 30 kg Evidence: FDA accelerated approval for a narrow indication
Epithalon
Epithalon is claimed to slow aging by affecting telomeres, but the supporting experiment observed telomere-related changes only in cultured cells. It did not test injections, physical function, appearance, disease or lifespan in people. [1,2]
Status: Not FDA-approved. [1–2] Evidence: Cell-line and limited historical research; no injected anti-aging outcome evidence
GHK-Cu
GHK-Cu carries copper and affects how skin cells make collagen and rebuild surrounding tissue. Small studies of specific topical products examined wrinkles, post-laser care and diabetic ulcers, with mixed results. They do not establish injection benefits. [1,3–7]
Status: Cosmetic use is not FDA approval. FDA separately flags injectable compounding risks. [6,7] Evidence: Limited topical human studies; injection benefits unestablished
IGF-1 LR3
IGF-1 LR3 is a modified growth signal claimed to increase muscle, strength and recovery. Its tissue-building effects were studied in cells and rats, not in controlled human training studies. The approved medicine mecasermin is a different molecule. [1–3]
Status: No FDA-approved IGF-1 LR3 product Evidence: Preclinical evidence
Ipamorelin
Ipamorelin triggers a short growth-hormone rise and is claimed to improve sleep, recovery, muscle and fat loss. Human studies measured the hormone response but did not demonstrate those wellness outcomes; a postoperative bowel-recovery trial found no significant efficacy difference. [1–3]
Status: Investigational use in the cited studies. [1,2] Evidence: Limited human studies; routine benefit unestablished
KLOW blend
KLOW is a non-standardized mixture of GHK-Cu, BPC-157, TB-500 and KPV claimed to improve skin, inflammation, pain and recovery. No human trial has tested the four ingredients together, and formulas may differ. [1–7]
Status: Not FDA-approved. FDA has identified significant safety concerns or major human-data gaps for injectable GHK-Cu, BPC-157, TB-500 and KPV. Evidence: No blend-specific clinical evidence
KPV
KPV is a short alpha-MSH fragment that reduced selected inflammation signals in cells and mouse colitis models. The hoped-for result is less skin or gut irritation, but no controlled human study has shown that benefit by any route. [1–3]
Status: Not FDA-approved. [1–3] Evidence: Preclinical evidence only for claimed uses
Melanotan II
Melanotan II activates melanocortin receptors and produced visible pigmentation and erections in very small early human studies. Those noticeable effects help explain its popularity, but nausea, fatigue, product inconsistency and unknown long-term safety remain important. [1,2,6,7]
Status: Not approved as a tanning agent in Australia; TGA warns against use. [6] Evidence: Small human studies; serious safety concerns
MOTS-c
MOTS-c is a mitochondrial peptide involved in how cells respond when energy is limited. Treatment changed glucose use and performance in mice, but human research observed the body's own exercise response rather than testing injections. [1–3]
Status: No established clinical treatment in the cited sources. [1–3] Evidence: Preclinical treatment evidence
NAD+
NAD+ is a molecule cells use for energy production, signaling and DNA repair. Injections are claimed to improve energy, clarity, recovery, cravings and aging, but a 2026 review found no eligible outcome trials of injected NAD+ itself. [1,2]
Status: Not FDA-approved. [1–2] Evidence: Biochemical rationale; clinical wellness claims unestablished
PT-141
PT-141 is bremelanotide, which acts on brain pathways linked to sexual desire rather than directly increasing blood flow. Vyleesi is approved for certain premenopausal women with acquired, generalized HSDD. [1–3]
Status: FDA-approved as Vyleesi for a specific HSDD indication Evidence: Approved for a defined HSDD population
Retatrutide
Retatrutide activates GLP-1, GIP and glucagon receptors to reduce hunger, increase fullness and affect glucose and energy use. Lilly reported substantial Phase 3 weight loss in May 2026, but the full results remain unpublished and the drug is investigational. [1–3]
Status: Not FDA-approved. FDA says retatrutide cannot be compounded under federal law. [1–3] Evidence: Phase 3 sponsor topline; investigational and not FDA-approved
Selank
Selank is a synthetic peptide studied with the goal of reducing anxious thoughts and physical tension without heavy sedation. The often-cited study compared it with medazepam and had no placebo group, so the size and reliability of the benefit remain unclear. [1,2]
Status: Not FDA-approved. [1–2] Evidence: Small active-comparator study; no FDA approval
Semaglutide
Semaglutide copies the GLP-1 signal, helping people feel full sooner, slowing food leaving the stomach and improving glucose control. That can support weight loss or diabetes treatment, depending on the exact approved product. [1–3]
Status: FDA-approved only for the named products and labeled uses. [1–3] Evidence: FDA-approved medicines; instructions are product and indication specific
Semax
Semax is a synthetic ACTH fragment studied in neurological care with the aim of supporting recovery after reduced brain blood flow. That condition-specific literature does not establish sharper focus, memory or motivation in healthy users. [1,2]
Status: Not FDA-approved. [1–2] Evidence: Limited regional clinical literature; U.S. uses unapproved
Sermorelin
Sermorelin copies the signal that tells the pituitary gland to release growth hormone. It is claimed to improve sleep, muscle, fat loss, recovery and aging in adults, but a hormone increase does not prove those day-to-day benefits. [1–3]
Status: Not FDA-approved. [1–2] Evidence: Historical diagnostic/pediatric product; claimed adult uses unestablished
Survodutide
Survodutide combines GLP-1 and glucagon receptor activity to reduce hunger, increase fullness and affect liver fat and energy use. Phase 3 trial participants lost substantially more weight than placebo, but the product remains investigational. [1–3]
Status: Not FDA-approved. [1–3] Evidence: Published Phase 3 obesity trial; still investigational
TB-500
TB-500 is described as a short fragment related to thymosin beta-4 and is claimed to reduce pain and speed tendon, ligament or muscle recovery. The cited fragment study was performed in horses for drug detection, not human healing. [1–3]
Status: No FDA-approved TB-500 product Evidence: Human treatment evidence not established
Tesamorelin
Tesamorelin raises growth hormone and IGF-1 and is approved to reduce visceral abdominal fat in adults with HIV-associated lipodystrophy. That imaging-measured benefit is not general weight loss, anti-aging or bodybuilding. [1–3]
Status: FDA-approved as Egrifta for adults with HIV-associated lipodystrophy Evidence: Approved for HIV-associated lipodystrophy
Tirzepatide
Tirzepatide copies GIP and GLP-1 signals, helping people feel full with less food and improving glucose control. It is the active ingredient in Mounjaro and Zepbound, with product-specific approved uses. [1–3]
Status: FDA-approved only for the named products and labeled uses. [1–3] Evidence: FDA-approved medicines with direct comparative trial evidence
How to use the index
Each profile separates product instructions from research protocols. Do not transfer doses, preparation instructions, storage periods, routes or adverse-event rates from one product to another.